https://www.selleckchem.com/pr....oducts/wnt-agonist-1
Emicizumab is a bispecific antibody exerting cofactor function of FVIIIa irrespective of the presence of FVIII inhibitors. Long-term data of phase 1/2 and phase 3 studies have been accumulated. Various questions such as indicated patients, ITI, application to PUPs, hemostatic treatment including surgeries, and emicizumab-related morbidity remain to be solved. The review describes the mode of action, data from pre-/post-marketing and ongoing clinical studies according to PubMed search and our own works. For patients with a persiste
Like
Comment
Share
